| Patents for A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (171,128) |
|---|
| 05/28/2013 | CA2609702C Antibody conjugates via heterobifunctional peg linkers |
| 05/28/2013 | CA2599733C Methods and compositons for modified release of nutritional supplements |
| 05/28/2013 | CA2588338C Compositions comprising azelastine and methods of use thereof |
| 05/28/2013 | CA2587677C High concentration self-microemulsifying coenzyme q10 preparations for nutritional use |
| 05/28/2013 | CA2559748C Treatment and prevention of benign breast disease with 4-hydroxy tamoxifen |
| 05/28/2013 | CA2532475C Formulation for a protein pharmaceutical without added human serum albumin (hsa) |
| 05/28/2013 | CA2477734C Suramin and derivatives thereof as topical microbicide and contraceptive |
| 05/28/2013 | CA2476935C Drug delivery system for subconjunctival administration of fine particles |
| 05/28/2013 | CA2476773C Monoclonal antibodies against extracellular loops of c5ar |
| 05/28/2013 | CA2473970C Uniform films for rapid dissolve dosage form incorporating taste-masking compositions |
| 05/28/2013 | CA2459769C Igf-1 as feline vaccine adjuvant, in particular against feline retroviruses |
| 05/28/2013 | CA2381468C Percutaneous absorption preparations containing melatonin receptor agonist for percutaneous treatment of sleep disorders |
| 05/28/2013 | CA2323210C Enhancement of intracellular delivery and tissue targeting of drugs and genes |
| 05/28/2013 | CA2240292C Recombinant fusion proteins to growth hormone and serum albumin |
| 05/23/2013 | WO2013075048A1 Methods of treating epidermal growth factor deletion mutant viii related disorders |
| 05/23/2013 | WO2013074616A1 Autoclavable suspensions of cyclosporin a form 2 |
| 05/23/2013 | WO2013074610A1 Sustained action formulation of cyclosporin form 2 |
| 05/23/2013 | WO2013074205A1 Liquid-filled hard gel capsule pharmaceutical formulations |
| 05/23/2013 | WO2013074055A1 Method for restoring and rejuvenating the human body and a pharmaceutical composition for implementation thereof |
| 05/23/2013 | WO2013073667A1 Intestinal fibrosis treatment agent |
| 05/23/2013 | WO2013073642A1 Gel of reduced pyrroloquinoline quinone |
| 05/23/2013 | WO2013073620A1 Carotenoid-containing composition and method for producing same |
| 05/23/2013 | WO2013073480A1 Cationic lipid having improved intracellular kinetics |
| 05/23/2013 | WO2013073454A2 Controlled release composition for physiologically active substance |
| 05/23/2013 | WO2013072813A2 Cytotoxic peptides and antibody drug conjugates thereof |
| 05/23/2013 | WO2013072767A1 Compositions and preconcentrates comprising at least one salicylate and omega-3 fatty acid oil mixture |
| 05/23/2013 | WO2013072676A1 Film-forming formulation |
| 05/23/2013 | WO2013072563A1 Drug delivery system for sustained delivery of bioactive agents |
| 05/23/2013 | WO2013072526A1 Selective imaging of actin in live native cells |
| 05/23/2013 | WO2013072332A1 Methods of using antagonists of bitter taste receptors |
| 05/23/2013 | WO2013072329A1 Pharmaceutical solid compositions containing ibuprofen salts |
| 05/23/2013 | WO2013072304A1 Single-dose pharmaceutical preparation of thyroid hormones t3 and/or t4 |
| 05/23/2013 | WO2013072290A1 Single unit dosage formulations of sevelamer and fat soluble vitamins and surface active agents |
| 05/23/2013 | WO2013072051A1 Nanoparticle compositions for generation of regulatory t cells and treatment of autoimmune diseases and other chronic inflammatory conditions |
| 05/23/2013 | WO2013071457A1 Injectable veterinary composition for controlled, sustained release of ceftiofur and florfenicol in animal species, based on polyhydroxybutyrate hydroxyvalerate (phbv) microparticles |
| 05/23/2013 | WO2013071356A1 Collagen-like silk genes |
| 05/23/2013 | WO2013049531A3 Multilayer magnetic micelle compositions and methods for their use |
| 05/23/2013 | WO2013024267A3 Stabilized compositions against ionising radiation |
| 05/23/2013 | WO2013022499A3 Polymer coated metal particles and uses related thereto |
| 05/23/2013 | US20130131804 Joint Repair Using Mesenchymal Stem Cells |
| 05/23/2013 | US20130131333 Cellulose interpolymers and method of oxidation |
| 05/23/2013 | US20130131192 Composition, method, and kit for alpha-1 proteinase inhibitor |
| 05/23/2013 | US20130131191 Additive for tablets |
| 05/23/2013 | US20130131190 Compositions comprising polymers prepared from 2-hydroxyalkyl acids |
| 05/23/2013 | US20130131188 Cosmetic Preparations |
| 05/23/2013 | US20130131187 Color metallic pigment, method for producing same, and coating composition and cosmetic containing same |
| 05/23/2013 | US20130131151 Method for photopolymerizing hydrogel using x-ray irradiation |
| 05/23/2013 | US20130131125 Therapeutic combination |
| 05/23/2013 | US20130131123 Oral Dosage Form Containing A Pde 4 Inhibitor As An Active Ingredient And Polyvinylpyrrolidon As Excipient |
| 05/23/2013 | US20130131087 Pharmaceutical Compositions |
| 05/23/2013 | US20130131052 Amelioration Of The Development Of Cataracts And Other Ophthalmic Diseases |
| 05/23/2013 | US20130131013 Cyclodextrin-based polymers for therapeutics delivery |
| 05/23/2013 | US20130131003 Orally disintegrating tablet containing acarbose |
| 05/23/2013 | US20130130981 Treatment using neublastin polypeptides |
| 05/23/2013 | US20130130348 Polymers for Functional Particles |
| 05/23/2013 | US20130129975 Medical or biochemical resin composition and resin molded product |
| 05/23/2013 | US20130129826 Tamper-resistant oral pharmaceutical dosage form comprising opioid antagonist and/or aversive agent, polyalkylene oxide and anionic polymer |
| 05/23/2013 | US20130129821 Ubiquinol and Alpha Lipoic Acid Compositions |
| 05/23/2013 | US20130129813 Targeted delivery using tissue-specific peptidomimetic ligands |
| 05/23/2013 | US20130129811 Cationic lipid |
| 05/23/2013 | US20130129807 Collagen-based implants for sustained delivery of drugs |
| 05/23/2013 | US20130129801 Aqueous dispersion comprising galactolipids and method for production thereof |
| 05/23/2013 | US20130129800 Hyaluronic acid based hydrogel and use thereof in surgery |
| 05/23/2013 | US20130129797 Polymeric compositions and methods of making and using thereof |
| 05/23/2013 | US20130129785 Methods and compositions for delivery of active agents |
| 05/23/2013 | US20130129756 Novel immunoadjuvant compounds and uses thereof |
| 05/23/2013 | US20130129712 Self-assembling hydrogels based on dicephalic peptide amphiphiles |
| 05/23/2013 | US20130129700 Formulations containing clopidogrel and sulfoalkyl ether cyclodextrin and methods of use |
| 05/23/2013 | US20130129665 Cyclodextrin-based polymers for therapeutics delivery |
| 05/23/2013 | US20130129663 Reverse thermal gels and uses therefor |
| 05/23/2013 | US20130129661 Material for skin and method for producing material for skin |
| 05/23/2013 | US20130129637 Method for producing reservoir layer for hoof treatment and reservoir layer |
| 05/23/2013 | US20130129634 Intrinsically magnetic hydroxyapatite |
| 05/23/2013 | US20130129630 Hyperthermia therapeutic agent delivery system |
| 05/23/2013 | US20130129627 Delivery of Nanoparticles to Neurons |
| 05/23/2013 | US20130129621 Integrin Receptor Antagonists and Their Methods of Use |
| 05/23/2013 | US20130129616 Gel composition for filling a breast milk duct prior to surgical excision of the duct or other breast tissue |
| 05/23/2013 | CA2856243A1 Rnai agents, compositions and methods of use thereof for treating transthyretin (ttr) associated diseases |
| 05/23/2013 | CA2856074A1 Autoclavable suspensions of cyclosporin a form 2 |
| 05/23/2013 | CA2856044A1 Sustained action formulation of cyclosporin form 2 |
| 05/23/2013 | CA2856016A1 Agent for treating fibrosis of the intestine |
| 05/23/2013 | CA2855818A1 Methods of treating cancer |
| 05/23/2013 | CA2855746A1 Methods of treating epidermal growth factor deletion mutant viii related disorders |
| 05/23/2013 | CA2855152A1 Collagen-like silk genes |
| 05/23/2013 | CA2853880A1 Single-dose pharmaceutical preparation of thyroid hormones t3 and/or t4 |
| 05/23/2013 | CA2852860A1 Cytotoxic peptides and antibody drug conjugates thereof |
| 05/23/2013 | CA2851209A1 Pharmaceutical solid compositions containing ibuprofen salts |
| 05/22/2013 | EP2594592A1 (nucleic acid)-polysaccharide complex |
| 05/22/2013 | EP2594583A1 Transferrin variants and conugates |
| 05/22/2013 | EP2594292A1 Novel drug delivery devices |
| 05/22/2013 | EP2594291A1 Hydrogel |
| 05/22/2013 | EP2594290A1 Selective imaging of actin in live native cells |
| 05/22/2013 | EP2594289A2 Use of carbon nanotubes for preventing or treating brain disease |
| 05/22/2013 | EP2594283A1 Aprotinin-based aerosol preparation for the treatment of viral respiratory infections |
| 05/22/2013 | EP2594277A1 Tablet containing ferric citrate |
| 05/22/2013 | EP2594269A1 Controlled release nucleated tablet |
| 05/22/2013 | EP2594266A1 Pharmaceutical solid compositions containing ibuprofen salts |
| 05/22/2013 | EP2594258A1 Oral gel comprising praziquantel |
| 05/22/2013 | EP2594254A1 Oil-based gel-like composition |
| 05/22/2013 | EP2593463A1 Formulations of rifaximin and uses thereof |